Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

Pharmacogenetics

Volumn 11, Issue 9, 2001, Pages 803-808

  Kidd, R S ^a   Curry, T B ^a   Gallagher, S ^a   Edeki, T ^a   Blaisdell, J ^a   Goldstein, J A ^a  

^a SHENANDOAH UNIVERSITY   (United States)

Author keywords

Cytochrome P450; Pharmacokinetics; Phenytoin; Polymorphism

Indexed keywords

CYTOCHROME P450 2C9; GLIPIZIDE; PHENYTOIN; TOLBUTAMIDE; WARFARIN;

ADULT; ALLELE; ARTICLE; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; NEGRO; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUTATION; PHENYTOIN; POLYMORPHISM, GENETIC; SEIZURES; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035217171     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200112000-00008     Document Type: Article

References (41)

1. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
2. Biochemistry and molecular biology of the human CYP2C subfamily
3. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
4. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
5. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
6. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
7. Cytochromes P450 mediating the N-demethylation of amitriptyline
8. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
9. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
10. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide, and nifedipine in an individual homozygous for the CYP2C9*3 allele
11. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
12. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
13. Determination of CYP2C9 allele frequencies and of a possible role in amino acid substitution in tolbutamide hydroxylase activity
14. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
15. The R1 44C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase
16. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
17. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus
18. Catalytic activity of three variants (IIe, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis
19. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
20. Allele frequency of new CYP2C9 allere (CYP2C9*4) in Caucasians and African Americans (AA)
21. The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934 - A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site
22. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
23. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
24. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
25. Metabolism of anticonvulsant drugs
26. The effect of different sulfonamides on phenytoin metabolism in man
27. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes
28. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes
29. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin
30. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetlcs
31. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
32. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
33. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
34. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
35. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
36. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
37. Lung cancer risk in relation to mephenytoin hydroxylation activity
38. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines
39. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
40. CYP2C9*3 allelic variant and bleeding complications
41. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18